Correction: Drug review: mTOR-inhibitor therapy in fetal cardiac rhabdomyoma-a tightrope walk

Affiliations

¹ Department of Obstetrics and Gynaecology, Medical University of Innsbruck, Innsbruck, Austria.
² Department of Paediatrics II (Neonatology), Medical University of Innsbruck, Innsbruck, Austria.
³ Department of Paediatrics III (Cardiology, Pulmonology, Allergology and Cystic Fibrosis), Medical University of Innsbruck, Innsbruck, Austria.

^# Contributed equally.

Published Erratum

Nadine Muschel et al. Front Pediatr. 2025.

. 2025 Sep 9:13:1694368.

doi: 10.3389/fped.2025.1694368. eCollection 2025.

¹ Department of Obstetrics and Gynaecology, Medical University of Innsbruck, Innsbruck, Austria.
² Department of Paediatrics II (Neonatology), Medical University of Innsbruck, Innsbruck, Austria.
³ Department of Paediatrics III (Cardiology, Pulmonology, Allergology and Cystic Fibrosis), Medical University of Innsbruck, Innsbruck, Austria.

^# Contributed equally.

Abstract

[This corrects the article DOI: 10.3389/fped.2025.1649341.].

Keywords: adverse effects; fetal cardiac tumor; re-entry tachycardia; rhabdomyoma; sirolimus.

Drug review: mTOR-inhibitor therapy in fetal cardiac rhabdomyoma-a tightrope walk.
Muschel N, Höck M, Griesmaier E, Azim SA, Ralser E, Schreiner C, Schermer E, Kiechl-Kohlendorfer U, Mutz-Dehbalaie I, Michel M. Muschel N, et al. Front Pediatr. 2025 Aug 26;13:1649341. doi: 10.3389/fped.2025.1649341. eCollection 2025. Front Pediatr. 2025. PMID: 40933704 Free PMC article.